Literature DB >> 17904173

PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).

Xiaoli Shen1, Ramanjaneya V R Mula, Jing Li, Nancy L Weigel, Miriam Falzon.   

Abstract

Parathyroid hormone-related protein (PTHrP) increases the growth and metastatic potential of prostate cancer cells, making it important to control PTHrP expression in these cells. 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] suppresses PTHrP expression and exerts an anti-proliferative effect in prostate carcinoma cells. We used the human prostate cancer cell line C4-2 as a model system to ask whether down-regulation of PTHrP expression by 1,25(OH)(2)D(3) plays a role in the anti-proliferative effects of 1,25(OH)(2)D(3). Since PTHrP increases the expression of the pro-invasive integrin alpha6beta4, we also asked whether 1,25(OH)(2)D(3) decreases integrin alpha6beta4 expression in C4-2 cells, and whether modulation of PTHrP expression by 1,25(OH)(2)D(3) plays a role in the effects of 1,25(OH)(2)D(3) on integrin alpha6beta4 expression. Two strategies were utilized to modulate PTHrP levels: overexpression of PTHrP (-36 to +139) and suppression of endogenous PTHrP expression using siRNAs. We report a direct correlation between PTHrP expression, C4-2 cell proliferation and integrin alpha6beta4 expression at the mRNA and cell surface protein level. Treatment of parental C4-2 cells with 1,25(OH)(2)D(3) decreased cell proliferation and integrin alpha6 and beta4 expression. These 1,25(OH)(2)D(3) effects were significantly attenuated in cells with suppressed PTHrP expression. 1,25(OH)(2)D(3) regulates PTHrP expression via a negative vitamin D response element (nVDRE) within the noncoding region of the PTHrP gene. The effects of 1,25(OH)(2)D(3) on cell proliferation and integrin alpha6beta4 expression were significantly attenuated in cells overexpressing PTHrP (-36 to +139), which lacks the nVDRE. These findings suggest that one of the pathways via which 1,25(OH)(2)D(3) exerts its anti-proliferative effects is through down-regulation of PTHrP expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904173      PMCID: PMC2134836          DOI: 10.1016/j.steroids.2007.08.003

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  51 in total

Review 1.  The physiology of parathyroid hormone-related protein.

Authors:  G J Strewler
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane.

Authors:  R Eskes; S Desagher; B Antonsson; J C Martinou
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

4.  Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide.

Authors:  M Falzon; P Du
Journal:  Endocrinology       Date:  2000-05       Impact factor: 4.736

Review 5.  Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway.

Authors:  Jacqueline Moreno; Aruna V Krishnan; Donna M Peehl; David Feldman
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

6.  PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells.

Authors:  Xiaoli Shen; Miriam Falzon
Journal:  Exp Cell Res       Date:  2006-08-17       Impact factor: 3.905

Review 7.  Molecular mechanisms of osteolytic bone metastases.

Authors:  T A Guise
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

Review 8.  Prostate carcinoma: production of bioactive factors.

Authors:  L J Deftos
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

Review 9.  Role of Wnts in prostate cancer bone metastases.

Authors:  Christopher L Hall; Sona Kang; Ormond A MacDougald; Evan T Keller
Journal:  J Cell Biochem       Date:  2006-03-01       Impact factor: 4.429

10.  Prostate cancer.

Authors:  David F Penson; June M Chan
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more
  7 in total

1.  1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V Mula; Miriam Falzon
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

2.  Parathyroid hormone-related protein regulates integrin α6 and β4 levels via transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V R Mula; Miriam Falzon
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

3.  Nuclear PTHrP targeting regulates PTHrP secretion and enhances LoVo cell growth and survival.

Authors:  V Bhatia; M K Saini; M Falzon
Journal:  Regul Pept       Date:  2009-07-17

4.  Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.

Authors:  Vandanajay Bhatia; Ramanjaneya V Mula; Nancy L Weigel; Miriam Falzon
Journal:  Mol Cancer Res       Date:  2009-07-07       Impact factor: 5.852

5.  EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Authors:  Vandanajay Bhatia; Manjit K Saini; Xiaoli Shen; Lian X Bi; Suimin Qiu; Nancy L Weigel; Miriam Falzon
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

Review 6.  Interaction of vitamin D with membrane-based signaling pathways.

Authors:  María Jesús Larriba; José Manuel González-Sancho; Félix Bonilla; Alberto Muñoz
Journal:  Front Physiol       Date:  2014-02-18       Impact factor: 4.566

Review 7.  Integrins in the Spotlight of Cancer.

Authors:  Daniela Bianconi; Matthias Unseld; Gerald W Prager
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.